A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev

Active, not recruitingOBSERVATIONAL
Enrollment

501

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

August 31, 2027

Study Completion Date

March 31, 2028

Conditions
Venous Thrombosis
Interventions
DRUG

Atezolizumab

atezolizumab 1200mg and bevacizumab 15mg/kg

PROCEDURE

Surgery

hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg

Trial Locations (23)

200000

Zhongshan hospital, Fudan University, Shanghai

Unknown

Beijing Cancer Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Science, Beijing

Peking Union Medical College Hospital, Beijing

Peking Univerty People's Hospital, Beijing

Xiangya Hospital of Central South University, Changsha

West China Hospital of Sichuan University, Chengdu

Fujian Provincial Hospital, Fuzhou

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

Sun Yat-sen University Cancer Center, Guangzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Anhui Provincial Hospital, Hefei

The Second Affiliated Hospital Kunming Medical University, Kunming

The First Hospital of Lanzhou University, Lanzhou

Jiangsu Provine People Hospital, Nanjing

Guangxi Medical University Cancer Hospital, Nanning

The First Affiliated Hospital Of Guangxi Medical University, Nanning

Shanghai Jiao Tong University Ruijin Hospital, Shanghai

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Tongji Hospital of Tongji Medical College of HUST, Wuhan

Henan Province People Hospital, Zhengzhou

All Listed Sponsors
lead

Jia Fan

OTHER